Salesforce Stockholders Approve 34 Million New Shares for Equity Incentive Plan
CRM sits 28% above its 52-week low of $163.52 on elevated volume (2.0× avg).
Summary
Salesforce stockholders approved the authorization of an additional 34 million shares for its equity incentive plan, representing significant potential future dilution.
Key Events · Financing and Capital Events · CRM
-
Equity Incentive Plan Expanded
Stockholders approved an amendment to the 2013 Equity Incentive Plan, increasing the number of shares reserved for issuance by an additional 34 million shares and extending the plan's term to March 26, 2036.
-
Employee Stock Purchase Plan Increased
An amendment to the 2004 Employee Stock Purchase Plan was approved, increasing the number of shares reserved for employee purchases.
-
Director Re-elections
All twelve nominated directors, including Marc Benioff and Parker Harris, were re-elected to the Board.
-
Executive Compensation Approved
The advisory vote to approve the fiscal 2026 compensation of named executive officers passed.
Analysis · CRM · Technology
Stockholders approved an amendment to the 2013 Equity Incentive Plan, authorizing an additional 34 million shares for future issuance. This represents a substantial potential dilution for existing shareholders, enabling the company to continue using equity for employee compensation and retention. While necessary for talent management, this authorization creates an overhang of potential future share supply.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRM was trading at $209.76 on NYSE in the Technology sector, with a market capitalization of approximately $171.7B. The 52-week trading range was $163.52 to $276.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.